TCR² Therapeutics Inc.

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi LLP is investigating TCR² (NASDAQ: TCRR) for possible breaches of fiduciary duty and other violations of law in its transaction with Adaptimmune.

Ademi LLP alleges TCR²’s financial outlook and prospects are excellent and yet TCR² shareholders are expected to receive only 1.5117 Adaptimmune ADS for each TCR² share. The transaction agreement unreasonably limits competing bids for TCR² by imposing a significant penalty if TCR² accepts a superior bid. TCR² insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of TCR²’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for TCR².